UNSPSC 51112517: Mannomustine hydrochloride

This classification denotes a nitrogen mustard compound C10H22Cl2N2O4.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UOZ2JJZ3I5, chemically known as d-mannitol, 1,6-bis((2-chloroethyl)amino)-1,6-dideoxy-, dihydrochloride, but more generally known as mannomustine hydrochloride, which bears US NIH Compound Identifier 9884430. Most nations, for tariff and trade purposes, schedule mannomustine hydrochloride under HS 29221980 and SITC 51461. As of Q4 2014, MANNOMUSTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: C(CCL)NC[C@H]([C@H]([C@@H]([C@@H](CNCCCL)O)O)O)O.CL.CL.

UNSPSC 51112517 Mannomustine hydrochloride is a Commodity code covering a specific pharmaceutical active ingredient used in chemotherapy and immunosuppressive treatments. State and local procurement activity under this code is minimal and highly specialized, limited primarily to health and human services agencies, state pharmacy benefit programs, and institutional healthcare systems that stock or procure this drug for eligible patients. Recent solicitation activity does not reflect direct commodity purchasing of the drug itself but rather solicitation of vendor capabilities and contracting arrangements related to pharmacy benefit management and pharmaceutical distribution channels.

The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather market intelligence on direct-to-manufacturer prescription programs, with a response deadline of April 3, 2026. This exploratory solicitation does not represent a formal competitive procurement for mannomustine hydrochloride as a finished pharmaceutical product; instead, it seeks vendor input on establishing direct contracting relationships between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements. The RFI documents no award value, budget allocation, or specific drug procurement volume. Geographic activity under this code is concentrated in Texas, where state health agencies manage pharmacy benefit procurement for employee and retiree populations. The narrow and specialized nature of this Commodity code—a single active pharmaceutical ingredient used in limited clinical contexts—means that procurement volume and issuing-body diversity remain low compared to broader pharmaceutical or health supply categories.